MILIND JAVLE to Administration, Intravenous
This is a "connection" page, showing publications MILIND JAVLE has written about Administration, Intravenous.
Connection Strength
0.080
-
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
Score: 0.042
-
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899.
Score: 0.038